Portalac syrup 667 mg / ml fl. 250ml

Release form, composition and packaging The syrup is transparent, viscous, from colorless to brownish-yellow.

1 ml

lactulose

667 mg

purified water.

250 ml - polyethylene bottles (1) - cardboard packs. 500 ml - polyethylene bottles (1) - cardboard packs. Pharmacological action Laxative. It causes a change in the flora of the colon (an increase in the number of lactobacilli), which leads to an increase in acidity in the lumen of the colon and stimulates its peristalsis. Along with this, the volume increases and the feces soften. As a result, a laxative effect develops, without a direct effect on the mucous membrane and smooth muscles of the colon. Under the action of lactulose, there is also the absorption of ammonia in the colon, a decrease in the formation of nitrogen-containing toxic substances in its proximal section and, accordingly, their absorption into the vena cava system. Has the ability to inhibit the growth of Salmonella in the colon.Does not decrease absorption of vitamins and is not addictive. Virtually not absorbed from the intestine. Pharmacokinetics After ingestion, lactulose by passage passes into the colon, where it is metabolized by bacteria that break down sugar. As a result, simple organic acids are formed - mainly lactic acid and to a lesser extent acetic and formic acid. A small amount of lactulose is absorbed and excreted in the urine unchanged. Indications for use Constipation, incl. chronic, during pregnancy, hemorrhoids after surgery on the colon and / or in the anal area, to prepare for surgery on the colon for softening the stool (facilitating bowel movements) with pain syndrome after removal of hemorrhoids hepatic encephalopathy hepatic precoma and coma.Contraindications to use Rectal bleeding colo-, ileostomy suspicion of appendicitis galactosemia patients with lactose intolerance, lactase deficiency, glucose-galactose malabsorption intestinal obstruction hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses higher than recommended, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses higher than recommended, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.hypersensitivity to lactulose. Dosing regimenIndividual, depending on age and indications. Side effect From the digestive system: in the first days of admission, flatulence may appear (usually gradually decreases and disappears) when taken in doses higher than recommended, abdominal pain and diarrhea are possible, which requires dose adjustment rarely - nausea.

When used in high doses for a long time for the prevention and treatment of hepatic precoma and coma, diarrhea and impaired water-electrolyte metabolism are possible.

From the nervous system: rarely - convulsions, headache, dizziness.

Others: possibly - allergic reactions

rarely - arrhythmias, myalgia, increased fatigue, weakness. Drug interaction With simultaneous use with broad-spectrum antibiotics, the therapeutic efficacy of lactulose may decrease.

With the simultaneous use of lactulose can disrupt the release of active substances from enteric drugs with pH-dependent release due to the fact that it lowers the pH of the intestinal contents. Application during pregnancy and lactation. should be used for abdominal pain, nausea, vomiting without verification of the diagnosis.

Use with caution in patients with gastrocardial syndrome.

In such cases, treatment should be started with low doses and increased gradually to avoid the development of flatulence.

Use with caution in patients with diabetes mellitus, especially with inflammatory lesions of the colon.

With long-term treatment (more than 6 months), the level of potassium, chlorine and carbon dioxide in the blood plasma should be regularly monitored.

If diarrhea occurs, lactulose should be discontinued.

Name ENG

PORTALAK

Clinical and pharmacological group

A laxative drug with osmotic properties.

Hypoammonic remedy

ATX code

Lactulose

Dosage

667mg / ml x 250ml

Structure

100 ml of syrup contains: active ingredient: lactulose concentrate - 96 ml (containing: lactulose - 69.4 g, water - 65.6 ml)

auxiliary substances: water -4 ml.

INN / Active ingredient

lactulose

Storage conditions and periods

At a temperature not exceeding 25 degrees (do not freeze).

Expiration date: 3 years

Specifications

Category

Laxatives

Scope of the drug

Gastrointestinal tract

Release form

Syrup

Manufacturer country

Croatia

Package quantity, pcs

one

Scope of application

Gastroenterology

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Belupo

The amount of the dosage form in the primary package

250 ml

Primary packaging type

Polyethylene bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Laxative

Anatomical and therapeutic characteristics

A06AD11 Lactulose

Dosage form

Syrup

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

667 mg

Package weight, g

395